These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 25687821)

  • 1. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibition: new treatment options in urologic cancer.
    De Maeseneer DJ; Delafontaine B; Rottey S
    Acta Clin Belg; 2017 Feb; 72(1):24-28. PubMed ID: 28151378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to PD1/PDL1 checkpoint inhibition.
    O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
    Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.
    Nowicki TS; Anderson JL; Federman N
    Pediatr Res; 2016 Mar; 79(3):371-7. PubMed ID: 26595537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD1/PDL1 induced psoriasis.
    Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
    Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
    Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
    Front Immunol; 2022; 13():862084. PubMed ID: 35493449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
    Berghmans T; Grigoriu B; Sculier JP; Meert AP
    Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.